XOMA Royalty Corp
XOMAP
Company Profile
Business description
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
The most overvalued commodity sector right now
With recent movements in commodity prices, we identify shares to avoid at current prices.
stocks
Arcadium a steal but how much difference will it make to Rio Tinto
Rio have made a counter-cyclical move to buy some of the world's lowest-cost lithium assets. Our mining analyst Jon Mills says the firm is still all about iron ore for now.
stocks
Are we in the last days of ASX dividend dominance?
Some of the largest ASX listed companies are potential dividend traps. What should income investors do?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,581.10 | 17.50 | -0.20% |
| CAC 40 | 7,521.97 | 80.09 | -1.05% |
| DAX 40 | 19,486.19 | 22.10 | -0.11% |
| Dow JONES (US) | 42,740.42 | 324.80 | -0.75% |
| FTSE 100 | 8,249.28 | 43.38 | -0.52% |
| HKSE | 20,407.20 | 88.41 | 0.44% |
| NASDAQ | 18,315.59 | 187.10 | -1.01% |
| Nikkei 225 | 39,093.46 | 817.09 | -2.05% |
| NZX 50 Index | 12,697.05 | 143.72 | -1.12% |
| S&P 500 | 5,815.26 | 44.59 | -0.76% |
| S&P/ASX 200 | 8,308.60 | 9.80 | -0.12% |
| SSE Composite Index | 3,220.27 | 18.97 | 0.59% |